Anti-beta 2 Glycoprotein 1 Antibody (anti-β2 GP1 Ab)

Coagulation

Description

The Anti-Beta2 Glycoprotein antibody test (IgG) is performed as part of the Lupus screen to detect antiphospholipid antibodies.

Antiphospholipid antibodies are a group of antibodies which include lupus anticoagulant, anticardiolipin antibodies (IgG or IgM) and anti-β2-glycoprotein-1 antibodies (IgG) which are associated with thrombosis and pregnancy loss/morbidity. Antiphospholipid syndrome is characterised by persistent positivity of these antibodies together with the clinical symptoms.

Β2-GP1 is a complement control protein and a natural inhibitor of coagulation which can bind to phospholipids complexed with plasma proteins resulting in a conformational change and exposure of epitopes to allow for the binding of autoantibodies.

In Sheffield Laboratory Medicine Anti-β2-GP1 antibodies are measured by automated immunoassays using chemiluminescent technology.

Indications

Antiphospholipid antibodies can be found in patients with Antiphospholipid Syndrome either in isolation or in association with other autoimmune disorders such as systemic lupus erythematous.

Sample Type

Plain serum x 1

Reference Range

Reference range is indicated on the report.

Turnaround Time

Within 2 weeks

Testing Frequency

Twice weekly

External Notes

The accuracy of all coagulation tests is greatly influenced by pre analytical variables. It is essential that sample quality is given the highest of priorities. Samples which fail to meet quality criteria including age of sample, specimen fill ( >90% ), haemolysed, clotted or activated samples will be rejected and a repeat sample requested.

Patient Preparation

No special requirements.

References

PG De Groot. B2-glycoprotein1: evolution, structure and function. JTH 2011,9,1275-1284.

Your contact for this test

Kieron Hickey

Thrombophilia Section Lead and Deputy Laboratory Manager - Coagulation

You are enquiring about

Anti-beta 2 Glycoprotein 1 Antibody (anti-β2 GP1 Ab)